BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17726865)

  • 1. [Hemostatic disturbances in chronic myeloid leukemia].
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Bielis L
    Wiad Lek; 2007; 60(3-4):138-42. PubMed ID: 17726865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Haemostatic disturbances in essential thrombocythosis].
    Rośc D; Gadomska G; Kremplewska-Nalezyta E; Bielis L
    Przegl Lek; 2007; 64(3):121-3. PubMed ID: 17941461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
    Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
    Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
    Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
    Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selected parameters of hemostasis in patients with myeloproliferative neoplasms.
    Gadomska G; Rość D; Stankowska K; Boinska J; Ruszkowska-Ciastek B; Wieczór R
    Blood Coagul Fibrinolysis; 2014 Jul; 25(5):464-70. PubMed ID: 24509338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer.
    Nanninga PB; van Teunenbroek A; Veenhof CH; Büller HR; ten Cate JW
    Thromb Haemost; 1990 Nov; 64(3):361-4. PubMed ID: 1710832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fibrinolytic system in bronchial asthma after prednisone treatment].
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Pol Merkur Lekarski; 2000 Jan; 7(43):9-11. PubMed ID: 10765644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
    Raaphorst J; Johan Groeneveld AB; Bossink AW; Erik Hack C
    Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes].
    Rość D; Drewniak W; Kotschy M; Graczykowska-Koczorowska A; Raukuć D
    Pol Merkur Lekarski; 1997 Jan; 2(7):24-5. PubMed ID: 9296893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemostatic alterations associated with supraceliac aortic cross-clamping.
    Anagnostopoulos PV; Shepard AD; Pipinos II; Raman SB; Chaudhry PA; Mishima T; Morita H; Suzuki G
    J Vasc Surg; 2002 Jan; 35(1):100-8. PubMed ID: 11802139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A; Wiman B; Schulman S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis.
    Mezzano D; Tagle R; Panes O; Pérez M; Downey P; Muñoz B; Aranda E; Barja P; Thambo S; González F; Mezzano S; Pereira J
    Thromb Haemost; 1996 Sep; 76(3):312-21. PubMed ID: 8883263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of chronic mercury poisoning on blood coagulation and fibrinolysis systems].
    Song YG
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2005 Dec; 23(6):405-7. PubMed ID: 16405768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of cause of cadaveric kidney donors death on fibrinolysis and blood coagulation processes.
    Ziętek Z; Iwan-Ziętek I; Sulikowski T; Sieńko J; Zukowski M; Kaczmarczyk M; Ciechanowicz A; Ostrowski M; Rość D; Kamiński M
    Transplant Proc; 2011 Oct; 43(8):2866-70. PubMed ID: 21996175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients.
    Salobir B; Sabovic M; Zupan IP; Ponikvar JB
    Ther Apher Dial; 2008 Apr; 12(2):133-6. PubMed ID: 18387161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of blood coagulation in patients undergoing postoperative blood salvage and re-infusion of unwashed whole blood after total knee arthroplasty.
    Biagini D; Filippucci E; Agnelli G; Pagliaricci S
    Thromb Res; 2004; 113(3-4):211-5. PubMed ID: 15140585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tissue plasminogen activator (t-PA) in aqueous humor of patients with cataract].
    Kotschy M; Kałuzny J; Kaniasty M; Zekanowska E; Kropińska E
    Klin Oczna; 1996 Mar; 98(3):201-3. PubMed ID: 9019589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.